Associate Professor Kelly Avery-Kiejda is the Manager of the Molecular Medicine Department, NSW Health Pathology, John Hunter Hospital and a Conjoint of the University of Newcastle.

Associate Professor completed a PhD at the University of Sydney in 2007. She has conducted research in breast cancer for over 20 years and is internationally recognised for work on the tumour suppressor p53.
Associate Professor Avery-Kiejda has extensive expertise in triple negative breast cancer (TNBC) biology and genome analysis. These analyses have led to the identification of novel markers of metastatic progression in TNBC. She currently manages a laboratory which performs testing on ~20K patients/year, specialising in genomic and cytogenomic analysis of germline, prenatal, haematological and solid tumour samples. The team are at the forefront of innovative diagnostic genomic pathology services, currently running the Medical Research Future Fund (MRFF) funded pharmacogenomic GeneScreen clinical trial and are a lead site for the genomic profiling conducted for Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT).
The team has extensive experience in performing genomic tests that are critical for determining cancer therapies and cancer progression in solid and haematological malignancies and offer bespoke NGS panels for hereditary cancers.